Follow Us
© 2026 Arizent. All rights reserved.
GLP-1 coverage decisions were the easy part. Two years in, employers are facing the harder question: what happens when people stop the medication. Discontinuation is common, weight often returns, and the spend starts over. For benefits leaders heading into 2027 renewals, the risk is no longer access; it is durability.
New drug pricing proposals could reshape employer pharmacy strategy, as benefit managers struggle to navigate rising prescription costs.
The companies have been looking for ways to gain an edge through deals with the firms that control drug benefits.
The U.S. agreed to exempt U.K. pharmaceutical products from tariffs.
From rising pharmacy spend to cancer care, 2026 healthcare costs pose new challenges, according to Business Group on Health's annual report.
Thirty-nine percent of millennials and 35% of Gen Z say access to weight loss drugs would improve their job satisfaction or productivity.
Using pooled resources, expertise and a wide range of perspectives, brokers and advisers can create a voice louder than Big Pharma.
Health plan sponsors must know the direct and indirect compensation paid to benefit brokers, consultants and medical and prescription drug claims administrators.
Complex and rare diseases cost three to five times more than chronic conditions — a staggering employer cost that will reach trillions by 2030.
Biden directly blamed Trump for the "chaos" surrounding the issue of abortion.
J&J allegedly mismanaged the company's prescription-drug benefits program, according to a lawsuit filed by an employee.
The rising cost of specialty medications is becoming too much for some employees.
Walmart’s insulin launch comes 15 years after it disrupted drugmakers and pharmacy chains by introducing a range of generic drugs for common ailments like allergies and high cholesterol.
With a $56,000 annual price tag, a new Alzheimer's treatment is turning up the volume on drug-pricing conflicts.
Beginning April 1, Humana will join a Cigna purchasing organization called Ascent Health Services to give it access to greater discounts from drugmakers.
“We recognize that we did not adequately acknowledge the epidemic unfolding in our communities or the terrible impact of opioid misuse," McKinsey said on its website.
Traditional PBMs shroud their compensation and drug costs.
Unlike private health insurance, Part D drug plans have no cap on patients’ 5% coinsurance costs once they hit $6,550 in drug spending, which forces patients to rely on financial assistance programs. These arrangements, however, do nothing to reduce drug prices.
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs.
A coalition of employers is on a crusade to cut company spending on drugs nationwide by simply noting the cheaper choices already available, drawing the ire of drugmakers.
